title: Characteristics and Prognostic Analysis of 69 Patients With Pulmonary Sarcomatoid Carcinoma.
abstract: Pulmonary sarcomatoid carcinoma (PSC) is a rare malignancy.
  
  
  
  A total of 69 patients with PSC treated at a single institution in southern China with long-term follow-up were evaluated in this study. We analyzed the clinical characteristics, immunohistochemical profiles, epidermal growth factor receptor mutation status, K-RAS mutation status, treatments, and prognosis.
  
  
  
  PSC mainly occurred in young male patients with a history of smoking. Most patients received multimodality treatments and the majority had early-stage disease. The median survival time was 19.1 months, and the 5-year survival rate was 17.4%. The patients without distant metastasis, with normal or higher body mass index (≥18.5), with normal hemoglobin, with smaller tumor size (≤4 cm), and those who received complete resection had significantly better overall survival (P<0.05). The patients with pleomorphic carcinoma had much worse prognosis. In a Cox regression model, M stage, pathology, and having received a complete resection were independent prognostic factors (P<0.05).
  
  
  
  PSC is a unique lung malignancy with poor prognosis. Patients receiving complete resection had better prognosis, likely a reflection of early-stage disease. Neither neoadjuvant nor adjuvant chemotherapy improved patient survival for those with early-stage disease. The retrospective design and small sample size limited the generalizability. Future multicenter collaborations may be necessary to determine the optimal treatment.
authors: Departments of *Thoracic Surgery †Medical Oncology ‡Intensive Care Unit §Pathology, State Key Laboratory of Oncology in South China/Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, P.R. China ∥Stanford University School of Medicine, Stanford, CA.
authors: Yongbin
authors: Y
authors: Lin
authors: Han
authors: H
authors: Yang
authors: Qingqing
authors: Q
authors: Cai
authors: Daofeng
authors: D
authors: Wang
authors: Huilan
authors: H
authors: Rao
authors: Suxia
authors: S
authors: Lin
authors: Hao
authors: H
authors: Long
authors: Jianhua
authors: J
authors: Fu
authors: Lanjun
authors: L
authors: Zhang
authors: Peng
authors: P
authors: Lin
authors: Guangchuan
authors: G
authors: Xu
authors: Tiehua
authors: T
authors: Rong
authors: Xiaoxing
authors: X
authors: Xiong
authors: Guowei
authors: G
authors: Ma
authors: Ying
authors: Y
authors: Liang
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002277:Carcinoma / Q000737:chemistry / Q000473:pathology* / Q000556:secondary / Q000628:therapy*; D018286:Carcinoma, Giant Cell / Q000737:chemistry / Q000556:secondary / Q000628:therapy; D002296:Carcinosarcoma / Q000737:chemistry / Q000556:secondary / Q000628:therapy*; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D066246:ErbB Receptors / Q000235:genetics; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007633:Keratins / Q000032:analysis; D008175:Lung Neoplasms / Q000737:chemistry / Q000473:pathology* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D018396:Mucin-1 / Q000032:analysis; D009687:Nuclear Proteins / Q000032:analysis; D011379:Prognosis; D016283:Proto-Oncogene Proteins p21(ras) / Q000235:genetics; D018202:Pulmonary Blastoma / Q000737:chemistry / Q000556:secondary / Q000628:therapy*; D009418:S100 Proteins / Q000032:analysis; D015996:Survival Rate; D000074482:Thyroid Nuclear Factor 1; D014157:Transcription Factors / Q000032:analysis; D014746:Vimentin / Q000032:analysis; D055815:Young Adult
chemical_list: C117307:KRAS protein, human; D018396:Mucin-1; D009687:Nuclear Proteins; D009418:S100 Proteins; D000074482:Thyroid Nuclear Factor 1; D014157:Transcription Factors; D014746:Vimentin; D007633:Keratins; C512478:EGFR protein, human; D066246:ErbB Receptors; D016283:Proto-Oncogene Proteins p21(ras)